Study assessing safety (MTD), toxicity and efficacy of increasing doses of cladribine in combination with standard dose of CPX-351 in relapsed/refractory AML (R/R AML) patients
Latest Information Update: 12 Jan 2023
At a glance
- Drugs Cladribine (Primary) ; Cytarabine/daunorubicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
Most Recent Events
- 12 Jan 2023 New trial record
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition